US focuses pharma supply chain scrutiny


The US Food and Drug Administration (FDA) has named 13 companies that will be allowed to import drug products into the US with reduced scrutiny. Each company will be permitted to import up to five products under expedited entry arrangements for a period of two years.

The FDA’s Secure Supply Chain Pilot Program is an effort to free up the agency’s resources to focus on areas where imports pose the greatest risk to patients and consumers. The scheme rewards manufacturers for voluntarily adopting best practice and integrating integrity and security into their supply chain operations.

The move comes in the wake of a string of product recalls and import bans as some elements of the pharma industry struggle to maintain appropriate quality standards.


Related Content

Reaching out

22 May 2014 Premium contentFeature

news image

Andy Extance surveys how pharma uses outsourcing in a variety of different ways

Business roundup

28 March 2012 Business

news image

Industry news, April 2012

Most Read

Women twice as likely to be hired for academic posts as men

17 April 2015 News and Analysis

news image

Experiment shows that faculty staff are more likely to pick women for job roles based on hypothetical CVs

Carbon nanotube-based sensor detects meat spoilage

23 April 2015 Research

news image

Electron density of cobalt porphyrin complexes key to meat freshness sensor

Most Commented

Oh, the humanities!

20 April 2015 The Crucible

news image

Science and the arts are equally essential to society, says Philip Ball. Don’t divide them by their differences

Relativity behind mercury's liquidity

21 June 2013 Research

news image

First evidence that relativistic effects are indeed responsible for mercury's low melting point